Gilead Sciences Inc Allovir, Inc. (ALVR) insider trading activity

Gilead Sciences Inc is > 10% Shareholder of Allovir, Inc.. Currently has a direct ownership of 16.6 Million shares of ALVR, which is worth approximately $7.65 Million. The most recent transaction as insider was on Jun 27, 2023, when has been sold 2,930,870 shares (Common Stock) at a price of $3.75 per share, resulting in proceeds of $10,990,762. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 16.6M

0% 3M change

0% 12M change

Total Value Held $7.65 Million

GILEAD SCIENCES INC Transaction History

Date	Transaction	Value	Shares Traded	Shares Held	Form
Jun 27 2023	BUY Open market or private purchase	$10,990,762 $3.75 p/Share	2,930,870 Added 14.98%	16,635,286 Common Stock

Also insider at

RCUS

Arcus Biosciences, Inc. Healthcare

> 10% Shareholder

KYTX

Kyverna Therapeutics, Inc.

> 10% Shareholder

XLO

Xilio Therapeutics, Inc. Healthcare

> 10% Shareholder

ASMB

ASSEMBLY BIOSCIENCES, INC. Healthcare

> 10% Shareholder

GSI